Napoleon Higgins
Psychiatry · Friendswood, TXNPI 1801814363
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $518,565 of the $718,589 with a category attached, or 72.2%. 30 manufacturers reported payments, led by Vanda Pharmaceuticals Inc. at 29.8% of the total. 2025 is the largest year on record at $268,611, 5.4 times the $50,062 reported in 2019. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,101 payments — averaging $652.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$214K
- Otsuka America Pharmaceutical, Inc.$155K
- Supernus Pharmaceuticals, Inc.$98K
- E.r. Squibb & Sons, L.L.C.$68K
- Noven Pharmaceuticals, Inc.$52K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$30K
- plus $101K from 24 others
Across 185 payments — averaging $2100.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$262K
- Acadia Pharmaceuticals Inc$68K
- Neurocrine Biosciences, Inc.$31K
- AbbVie$20K
- H. Lundbeck A S$6K
- Pfizer$500
What the payments were for
- Consulting fees$80,17111%
- Speaking & faculty fees$518,56572%
- Travel & lodging$89,44212%
- Food & beverage$30,4064%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 275 | $214,325 |
| Otsuka America Pharmaceutical, Inc. | 231 | $155,011 |
| Supernus Pharmaceuticals, Inc. | 174 | $98,233 |
| E.r. Squibb & Sons, L.L.C. | 73 | $68,430 |
| Noven Pharmaceuticals, Inc. | 43 | $51,520 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 35 | $30,272 |
| Axsome Therapeutics, Inc. | 22 | $25,680 |
| Collegium Pharmaceutical, Inc. | 16 | $15,918 |
| Sage Therapeutics, LLC | 17 | $15,877 |
| Neurocrine Biosciences, Inc. | 35 | $14,942 |
| Johnson & Johnson | 25 | $6,115 |
| Acadia Pharmaceuticals Inc | 14 | $6,002 |
| Biogen | 7 | $4,818 |
| Lundbeck LLC | 20 | $2,494 |
| Noven Therapeutics, LLC | 3 | $2,063 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $2,041 |
| AbbVie | 34 | $1,327 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $1,088 |
| Corium, LLC | 10 | $709 |
| Tris Pharma Inc | 7 | $514 |
| Teva Pharmaceuticals USA, Inc. | 3 | $344 |
| Boehringer Ingelheim | 4 | $295 |
| Sunovion Pharmaceuticals Inc. | 5 | $258 |
| Alkermes, Inc. | 2 | $116 |
| Ironshore Pharmaceuticals Inc. | 2 | $85 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $54 |
| Rhodes Pharmaceuticals L.p. | 1 | $20 |
| Neuronetics, Inc. | 1 | $15 |
| Livanova USA, Inc. | 1 | $13 |
| Neos Therapeutics, LP | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fanapt$211,630
- REXULTI$122,320
- QELBREE$90,194
- COBENFY$58,812
- Xelstrym$53,333
- Auvelity$25,416
- ABILIFY MAINTENA$22,748
- JORNAY PM$15,667
- INGREZZA$14,209
- REJOYN$11,995
- ABILIFY MYCITE$7,586
- INVEGA SUSTENNA$5,472
- INVEGA TRINZA$5,339
- Zurzuvae$3,262
- CAPLYTA$1,537
- VYEPTI$1,215
- TRINTELLIX$667
- NUPLAZID$611
- Azstarys$333
- VRAYLAR$190
How this compares
$718,589 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QelbreeViloxazine Hcl | 12 | $7,972 |
| Lisdexamfetamine Dimesylate | 28 | $7,018 |
| Quetiapine Fumarate | 21 | $1,377 |
| Lamotrigine | 34 | $724 |
| Hydroxyzine Hcl | 12 | $649 |
| Aripiprazole | 22 | $554 |
| Trazodone Hcl | 18 | $437 |
| Duloxetine Hcl | 27 | $275 |
| Buspirone Hcl | 23 | $209 |
| Citalopram HbrCitalopram Hydrobromide | 20 | $130 |
| Escitalopram Oxalate | 24 | $82 |
| Sertraline Hcl | 11 | $52 |
| Lorazepam | 15 | $29 |
| Clonazepam | 12 | $28 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Supernus Pharmaceuticals, Inc.Qelbree | $98,233 | $7,97212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Friendswood
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
- Alice MaoHouston$850K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.